Reply to: "Cutaneous squamous cell carcinoma progression during imiquimod treatment"

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: keenaq@gmail.com.
² Medstar Georgetown Melanoma and Skin Cancer Center, Georgetown University, Washington DC.
³ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Comment

Syril Keena T Que et al. J Am Acad Dermatol. 2018 Jul.

. 2018 Jul;79(1):e13.

doi: 10.1016/j.jaad.2018.03.026. Epub 2018 Mar 27.

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: keenaq@gmail.com.
² Medstar Georgetown Melanoma and Skin Cancer Center, Georgetown University, Washington DC.
³ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
Que SKT, Zwald FO, Schmults CD. Que SKT, et al. J Am Acad Dermatol. 2018 Feb;78(2):249-261. doi: 10.1016/j.jaad.2017.08.058. J Am Acad Dermatol. 2018. PMID: 29332705 Review.
Cutaneous squamous cell carcinoma progression during imiquimod treatment.
Dika E, Fanti PA, Lambertini M, Scarfì F, Ravaioli GM, Veronesi G, Baraldi C, Guglielmo A, Patrizi A. Dika E, et al. J Am Acad Dermatol. 2018 Jul;79(1):e11-e12. doi: 10.1016/j.jaad.2018.02.079. J Am Acad Dermatol. 2018. PMID: 29908822 No abstract available.